The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

Fatima  Cardoso

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; GlaxoSmithKline; Macrogenics; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Samsung Bioepis; Sanofi; Seagen; Teva

Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche

Aditya  Bardia

Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Merck (Inst); Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals

Research Funding - bioTheranostics

Fabrice  Andre

Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche

David W.  Cescon

Honoraria - Novartis; Pfizer

Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Merck; Novartis; Pfizer

Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Roche/Genentech (Inst)

Heather L.  McArthur

Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Genomic Health; Immunomedics; Lilly; Merck; Pfizer; Spectrum Pharmaceuticals

Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); ZIOPHARM Oncology (Inst)

Travel, Accommodations, Expenses - Amgen; Genentech; Immunomedics; Lilly; Lilly; Lilly; Lilly; Merck; Pfizer; Puma Biotechnology; Spectrum Pharmaceuticals

Other Relationship - Lilly; OBI Pharma

Melinda L.  Telli

Consulting or Advisory Role - Aduro Biotech; Celgene; Celldex; Genentech/Roche; Immunomedics; Merck; Pfizer; PharmaMar; Tesaro

Research Funding - Abbvie (Inst); Biothera (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst); Vertex (Inst)

Other Relationship - G1 Therapeutics

Sherene  Loi

Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)

Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)

Javier  Cortes

Stock and Other Ownership Interests  - MedSIR

Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche; Samsung

Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Daiichi Sankyo; ERYTECH Pharma; Merus; Polyphor; Roche; Seagen

Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche

Peter  Schmid

Employment - Roche (I)

Honoraria - AstraZeneca; Novartis; Pfizer; Roche

Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)

Nadia  Harbeck

Honoraria - Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche

Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Sandoz; Seagen

Research Funding - Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Carsten  Denkert

Stock and Other Ownership Interests  - Sividon Diagnostics

Honoraria - Amgen; Novartis; Pfizer; Roche; Teva

Consulting or Advisory Role - Amgen; Daiichi Sankyo; MSD Oncology

Patents, Royalties, Other Intellectual Property - EP20150702464 Patent application - therapy response; Patent application: EP18209672 - cancer immunotherapy; VMScope digital pathology software

Christian  Jackisch

Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro

Research Funding - Genomic Health (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche

Liyi  Jia

Employment - Merck

Stock and Other Ownership Interests  - Merck

Travel, Accommodations, Expenses - Merck

Kim M.  Hirshfield

Employment - Merck

Stock and Other Ownership Interests  - Merck

Travel, Accommodations, Expenses - Merck

Vassiliki  Karantza

Employment - Merck

Stock and Other Ownership Interests  - Merck